(Q34453268)

2 August 2017

title

Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma (English)

1 reference

Adaptive radiation therapy

2 August 2017

main subject

0 references

author name string

Tinger A

1

1 reference

2 August 2017

Waldron T

2

1 reference

2 August 2017

Peluso N

3

1 reference

2 August 2017

Katin MJ

4

1 reference

2 August 2017

Dosoretz DE

5

1 reference

2 August 2017

Blitzer PH

6

1 reference

2 August 2017

Rubenstein JH

7

1 reference

2 August 2017

Garton GR

8

1 reference

2 August 2017

Nakfoor BA

9

1 reference

2 August 2017

Patrice SJ

10

1 reference

2 August 2017

Chuang L

11

1 reference

2 August 2017

Orr JW Jr

12

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

International Journal of Radiation Oncology Biology Physics

2 August 2017

published in

1 reference

2 August 2017

volume

51

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

1256-1263

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Second-line chemotherapy for recurrent carcinoma of the ovary.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Concurrent chemotherapy and single high-dose plus whole abdominopelvic radiation for persistent ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Salvage whole-abdominal irradiation following chemotherapy failure in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Long-term survival with whole abdominopelvic irradiation in platinum-refractory persistent or recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Stage III ovarian carcinoma: an analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Hyperfractionation of whole-abdomen radiation therapy: salvage treatment of persistent ovarian carcinoma following chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Cellular response to low-dose irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901733-3

7 January 2021

10.1016/S0360-3016(01)01733-3

Identifiers

DOI

1 reference

2 August 2017

1 reference